Agenus Inc. , a leader in immuno-oncology innovation, announced the completion of its previously disclosed strategic collaboration with Zydus Lifesciences Ltd., a transaction designed to accelerate the global development and potential commercialization of Agenus’ botensilimab and balstilimab (BOT+BAL) combination immunotherapy…
Nicoya Life Sciences Expands Access to Gold-Standard SPR with Launch of Revo™ Platform Nicoya Life Sciences, Inc., a recognized leader in advanced biophysical characterization technologies for biologics discovery and development, has announced the launch of Revo™, a next-generation, label-free binding…
Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) science with a focus on healthy aging, today announced an expansion of consumer payment options for its flagship product, Tru Niagen, through a new partnership with Truemed. Through this…
Almirall, a global pharmaceutical company focused exclusively on medical dermatology, has announced plans to initiate a Phase III clinical study evaluating the efficacy and safety of lebrikizumab in adult patients with nummular eczema. The study, named LumiNE, is scheduled to…
InterAx Biotech Ltd (“InterAx”) and Alveus Therapeutics Inc. (“Alveus”) today announced the formation of a strategic research collaboration and licensing agreement focused on the development of a differentiated small-molecule therapeutic candidate for metabolic disease. The joint effort is designed to…
MTF Biologics and Kolosis BIO Launch Summit Matrix™ to Advance Orthopedic and Spinal Surgery Outcomes MTF Biologics, a global nonprofit dedicated to saving and healing lives through tissue and organ donation, transplantation, and medical research, has partnered with Kolosis BIO…
Integrated DNA Technologies Expands Synthetic Biology Portfolio Through Strategic Collaboration with Ansa Biotechnologies Integrated DNA Technologies (IDT), a Danaher company and a global leader in genomics, has announced a strategic collaboration with Ansa Biotechnologies, Inc., a pioneering company in DNA…
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for Fibromyalgia Management Axsome Therapeutics, Inc. a biopharmaceutical company pioneering innovative treatments for central nervous system (CNS) disorders, announced today that the first patient has been dosed in the FORWARD Phase…
Orion Revamps Packaging to Boost Patient Experience and Sustainability Since 2020, Orion has been systematically reimagining its product packaging with a dual focus on patient safety and environmental sustainability. This ongoing effort has touched every stage of the supply chain—from…
Sobi Exceeds 2025 Revenue and Adjusted EBITA Margin Outlook Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) today announced that its full-year 2025 revenue and adjusted EBITA margin have surpassed the company’s previous outlook, reflecting strong performance across its portfolio. Full-year…